PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant

BACKGROUND: Efficacy and quality of life (QoL) are key criteria for therapy selection in metastatic breast cancer (MBC). In hormone receptor positive (HR +) human epidermal growth factor receptor 2 negative (HER2 −) MBC, addition of targeted oral agents such as everolimus or a cycline-dependent kina...

Descripción completa

Detalles Bibliográficos
Autores principales: Degenhardt, Tom, Fasching, Peter A., Lüftner, Diana, Müller, Volkmar, Thomssen, Christoph, Schem, Christian, Witzel, Isabell, Decker, Thomas, Tesch, Hans, Kümmel, Sherko, Uleer, Christoph, Wuerstlein, Rachel, Hoffmann, Oliver, Warm, Mathias, Marschner, Norbert, Schinköthe, Timo, Kates, Ronald E., Schumacher, Johannes, Otremba, Burkhard, Zaiss, Matthias, Harbeck, Nadia, Schmidt, Marcus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10193608/
https://www.ncbi.nlm.nih.gov/pubmed/37198674
http://dx.doi.org/10.1186/s13063-023-07306-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10193608/
https://www.ncbi.nlm.nih.gov/pubmed/37198674
http://dx.doi.org/10.1186/s13063-023-07306-z

Ejemplares similares